LitCovid-sample-Enju  

PMC:7205724 / 113-441 JSONTXT 14 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T16 0-1 -COLON- denotes :
T17 2-17 NNS denotes Anti-antibodies
T18 17-18 -COMMA- denotes ,
T19 19-34 NNS denotes immunoglobulins
T20 34-35 -COMMA- denotes ,
T21 36-39 CC denotes and
T22 40-55 NNS denotes corticosteroids
T23 57-67 NNS denotes Highlights
T24 68-69 IN denotes •
T25 71-75 NNP denotes IVIG
T26 75-76 -COMMA- denotes ,
T27 77-85 VBN denotes combined
T28 86-90 IN denotes with
T29 91-104 NN denotes moderate-dose
T30 105-107 IN denotes of
T31 108-123 NNS denotes corticosteroids
T32 123-124 -COMMA- denotes ,
T33 125-130 MD denotes might
T34 131-138 VB denotes improve
T35 139-146 NN denotes patient
T36 147-155 NNS denotes outcomes
T37 157-158 PDT denotes •
T38 160-163 DT denotes The
T39 164-167 NN denotes use
T40 168-170 IN denotes of
T41 171-186 NNS denotes corticosteroids
T42 187-192 MD denotes might
T43 193-203 VB denotes accelerate
T44 204-212 NN denotes recovery
T45 213-217 IN denotes from
T46 218-226 NN denotes COVID-19
T47 228-229 PDT denotes •
T48 231-233 DT denotes No
T49 234-244 VBN denotes controlled
T50 245-253 JJ denotes clinical
T51 254-260 NNS denotes trials
T52 261-266 VBP denotes exist
T53 267-269 IN denotes on
T54 270-273 DT denotes the
T55 274-277 NN denotes use
T56 278-280 IN denotes of
T57 281-296 NNS denotes corticosteroids
T58 297-300 IN denotes for
T59 301-309 NN denotes COVID-19
T60 311-312 LS denotes •
T61 314-317 NN denotes IL6
T62 318-328 VBZ denotes correlates
R15 T17 T18 arg1Of Anti-antibodies,","
R16 T19 T18 arg2Of immunoglobulins,","
R17 T21 T20 arg1Of and,","
R18 T18 T21 arg1Of ",",and
R19 T22 T21 arg2Of corticosteroids,and
R20 T25 T24 arg1Of IVIG,•
R21 T25 T26 arg1Of IVIG,","
R22 T25 T27 arg2Of IVIG,combined
R23 T27 T28 arg1Of combined,with
R24 T29 T28 arg2Of moderate-dose,with
R25 T29 T30 arg1Of moderate-dose,of
R26 T31 T30 arg2Of corticosteroids,of
R27 T34 T32 arg1Of improve,","
R28 T25 T33 arg1Of IVIG,might
R29 T34 T33 arg2Of improve,might
R30 T25 T34 arg1Of IVIG,improve
R31 T36 T34 arg2Of outcomes,improve
R32 T36 T35 arg1Of outcomes,patient
R33 T39 T37 arg1Of use,•
R34 T39 T38 arg1Of use,The
R35 T39 T40 arg1Of use,of
R36 T41 T40 arg2Of corticosteroids,of
R37 T39 T42 arg1Of use,might
R38 T43 T42 arg2Of accelerate,might
R39 T39 T43 arg1Of use,accelerate
R40 T44 T43 arg2Of recovery,accelerate
R41 T44 T45 arg1Of recovery,from
R42 T46 T45 arg2Of COVID-19,from
R43 T51 T47 arg1Of trials,•
R44 T51 T48 arg1Of trials,No
R45 T51 T49 arg2Of trials,controlled
R46 T51 T50 arg1Of trials,clinical
R47 T51 T52 arg1Of trials,exist
R48 T52 T53 arg1Of exist,on
R49 T55 T53 arg2Of use,on
R50 T55 T54 arg1Of use,the
R51 T55 T56 arg1Of use,of
R52 T57 T56 arg2Of corticosteroids,of
R53 T55 T58 arg1Of use,for
R54 T59 T58 arg2Of COVID-19,for
R55 T62 T60 arg1Of correlates,•
R56 T61 T62 arg1Of IL6,correlates